Brief: Newron Announces Approval For Pivotal Phase Iii Enigma-Trs Program With Evenamide As Add-On Therapy In Patients With Treatment-Resistant Schizophrenia (Trs)
12/05/2025 12:31
May 12 (Reuters) - Newron Pharmaceuticals SpA NWRN.S: NEWRON ANNOUNCES APPROVAL FOR PIVOTAL PHASE III ENIGMA-TRS PROGRAM WITH EVENAMIDE AS ADD-ON THERAPY IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA (TRS) NEWRON PHARMACEUTICALS SPA: ENIGMA-TRS 1 12-WEEK STUDY RESULTS EXPECTED IN Q4 2026 Source text: ID:nBw9dWHbSa Further company coverage: NWRN.S ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study